1. Home
  2. ALT vs CHPT Comparison

ALT vs CHPT Comparison

Compare ALT & CHPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • CHPT
  • Stock Information
  • Founded
  • ALT 1997
  • CHPT 2007
  • Country
  • ALT United States
  • CHPT United States
  • Employees
  • ALT N/A
  • CHPT N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • CHPT Industrial Specialties
  • Sector
  • ALT Health Care
  • CHPT Consumer Discretionary
  • Exchange
  • ALT Nasdaq
  • CHPT Nasdaq
  • Market Cap
  • ALT 292.0M
  • CHPT 340.1M
  • IPO Year
  • ALT N/A
  • CHPT N/A
  • Fundamental
  • Price
  • ALT $3.83
  • CHPT $11.29
  • Analyst Decision
  • ALT Strong Buy
  • CHPT Hold
  • Analyst Count
  • ALT 6
  • CHPT 10
  • Target Price
  • ALT $17.40
  • CHPT $29.13
  • AVG Volume (30 Days)
  • ALT 3.0M
  • CHPT 532.9K
  • Earning Date
  • ALT 08-12-2025
  • CHPT 09-03-2025
  • Dividend Yield
  • ALT N/A
  • CHPT N/A
  • EPS Growth
  • ALT N/A
  • CHPT N/A
  • EPS
  • ALT N/A
  • CHPT N/A
  • Revenue
  • ALT $20,000.00
  • CHPT $407,681,000.00
  • Revenue This Year
  • ALT N/A
  • CHPT $2.79
  • Revenue Next Year
  • ALT $761,880.20
  • CHPT $24.20
  • P/E Ratio
  • ALT N/A
  • CHPT N/A
  • Revenue Growth
  • ALT N/A
  • CHPT N/A
  • 52 Week Low
  • ALT $2.90
  • CHPT $8.55
  • 52 Week High
  • ALT $11.16
  • CHPT $39.20
  • Technical
  • Relative Strength Index (RSI)
  • ALT 51.79
  • CHPT 47.09
  • Support Level
  • ALT $3.35
  • CHPT $11.41
  • Resistance Level
  • ALT $3.66
  • CHPT $11.85
  • Average True Range (ATR)
  • ALT 0.19
  • CHPT 0.59
  • MACD
  • ALT 0.07
  • CHPT 0.08
  • Stochastic Oscillator
  • ALT 86.18
  • CHPT 39.55

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About CHPT ChargePoint Holdings Inc.

ChargePoint Holdings Inc designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable consumers to locate, reserve, and authenticate EV charging. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. ChargePoint derives the majority of its revenue from the United States.

Share on Social Networks: